Results 91 to 100 of about 599,996 (240)

NF-κB regulates the effect of rosuvastatin’s rescue of the CD40L stimulated P4Hα1 inhibition in CD40L-stimulated HASMCs.

open access: yes, 2016
(A and B) Representative images of NF-κb nuclear translocation and NF-κB DNA binding activity after treated with 5 μg/ml rhsCD40L for 0, 15, 30, 60 and 120 min by immunofluorescence (A) and EMSA (B).
Wei Sun (93580)   +3 more
core   +1 more source

NF-κB affects E-box-mediated transcription.

open access: yes, 2021
Steady-state luciferase reporter assay in transiently transfected 293T cells. (A) NF-κB itself, in the absence of BMAL1/CLOCK (B/C), did not activate the E-box transcription from the 3xE-box::Luc or Per2-dLuc reporters (left, middle), but repressed BMAL1/
Yang Shen (66591)   +11 more
core   +1 more source

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand   +5 more
wiley   +1 more source

NF-κB regulates neuronal ankyrin-G via a negative feedback loop.

open access: yes, 2017
The axon initial segment (AIS) is a neuronal compartment defined by ankyrin-G expression. We here demonstrate that the IKK-complex co-localizes and interacts with the cytoskeletal anchor protein ankyrin-G in immunoprecipitation and proximity-ligation ...
Jochen Prehn (7895672)   +6 more
core   +3 more sources

NF-κB Activation Exacerbates, but Is not Required for Murine Bmpr2-Related Pulmonary Hypertension

open access: yesDiseases, 2014
Aim: The present study investigates the role of NF-κB in Bmpr2-related pulmonary hypertension (PH) using a murine model of PH with inducible overexpression of a cytoplasmic tail Bmpr2 mutation.
Megha Talati   +9 more
doaj   +1 more source

NF-κB activation in DEP-induced IL-6 and IL-8 expression in nasal fibroblasts.

open access: yes, 2016
(A) Nasal fibroblasts were treated DEP (50 μg/mL) in the presence or absence of BAY117082 (NF-κB inhibitor, 1 μM). Protein expression levels of NF-κB p50 were examined using western blotting.
Jae-Min Shin (5756)   +5 more
core   +1 more source

Several Alphaherpesviruses Interact Similarly with the NF-κB Pathway and Suppress NF-κB-Dependent Gene Expression

open access: yes, 2023
Alphaherpesvirus infection is associated with attenuation of different aspects of the host innate immune response that is elicited to confine primary infections at the mucosal epithelia.
Nicolás Romero   +15 more
core   +1 more source

Diabetes‐Associated Cognitive Impairment: Pathophysiology and Emerging Therapies

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Diabetes‐associated cognitive impairment (DACI) is a common yet underrecognized condition, manifesting along a spectrum from mild cognitive impairment to dementia. DACI encompasses patients who develop vascular dementia (VaD) or Alzheimer's disease (AD) with diabetes as a risk factor; however, in certain patients, particularly those lacking ...
Osman Corbali   +4 more
wiley   +1 more source

APOBEC3C‐Mediated NF‐κB Activation Promotes Malignant Progression of Gliomas

open access: yesImmunity, Inflammation and Disease
Objective To analyze the clinicopathological features, immunological characteristics, and prognostic value of APOBEC3C in gliomas, and to verify the specific mechanism by which it mediates the malignant progression of gliomas.
Chao Zhang   +6 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Home - About - Disclaimer - Privacy